FDA approves BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis
Go back to FDA approves BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis| INSMED (NASDAQ: INSM) | Delayed: 120.02 -1.8 (1.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $121.82 | 52 Week High | $19.30 | |||
| Open | $121.95 | 52 Week Low | $9.02 | |||
| Day High | $122.19 | P/E | N/A | |||
| Day Low | $119.52 | EPS | $-1.69 | |||
| Volume | 436,865 | |||||
